Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review
MD Ilie, A Vasiljevic, E Jouanneau… - Endocrine-related …, 2022 - erc.bioscientifica.com
Once temozolomide has failed, there is no recommended treatment option for pituitary
carcinomas and aggressive pituitary tumors. Immune-checkpoint inhibitors (ICIs) represent …
carcinomas and aggressive pituitary tumors. Immune-checkpoint inhibitors (ICIs) represent …
Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study
MD Ilie, C Villa, T Cuny, C Cortet, G Assie… - European journal of …, 2022 - academic.oup.com
Objective After temozolomide failure, no evidence-based treatment is available for pituitary
carcinomas (PCs) and aggressive pituitary tumors (APTs). To date, only 12 cases treated …
carcinomas (PCs) and aggressive pituitary tumors (APTs). To date, only 12 cases treated …
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors
After temozolomide failure, no evidence-based treatment option is currently available for
aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs). Moreover, once …
aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs). Moreover, once …
Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: two case reports and a review of the literature
C Duhamel, MD Ilie, H Salle, AS Nassouri… - Journal of Personalized …, 2020 - mdpi.com
Once temozolomide has failed, no other treatment is recommended for pituitary carcinomas
and aggressive pituitary tumors. Recently, the use of immune checkpoint inhibitors (ICIs) has …
and aggressive pituitary tumors. Recently, the use of immune checkpoint inhibitors (ICIs) has …
Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
B Sol, JMK de Filette, G Awada… - European Journal of …, 2021 - academic.oup.com
Background Pituitary carcinomas are rare but aggressive and require maximally coordinated
multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ) …
multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ) …
The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas
C Dai, S Liang, B Sun, J Kang - Frontiers in Endocrinology, 2020 - frontiersin.org
Most pituitary adenomas (PAs) are considered benign tumors, but approximately 0.2% can
present metastasis and are classified as pituitary carcinomas (PCs). Refractory PAs lie …
present metastasis and are classified as pituitary carcinomas (PCs). Refractory PAs lie …
Case report: a case of pituitary carcinoma treated with sequential dual immunotherapy and vascular endothelial growth factor inhibition therapy
LS Lamb, HW Sim, AI McCormack - Frontiers in Endocrinology, 2020 - frontiersin.org
Aggressive pituitary tumors (APTs) are associated with significant morbidity and mortality,
and effective treatment options are limited. Immune checkpoint inhibitors (ICIs) have …
and effective treatment options are limited. Immune checkpoint inhibitors (ICIs) have …
[HTML][HTML] Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study
N Majd, SG Waguespack, F Janku, S Fu… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Pituitary carcinoma is an aggressive tumor characterized by metastatic spread beyond the
sellar region. Symptoms can be debilitating due to hormonal excess and survival is poor …
sellar region. Symptoms can be debilitating due to hormonal excess and survival is poor …
Exploring the role of novel medical therapies for aggressive pituitary tumors: a review of the literature—“are we there yet?”
LS Lamb, HW Sim, AI McCormack - Cancers, 2020 - mdpi.com
Aggressive pituitary tumors account for up to 10% of pituitary tumors and are characterized
by resistance to medical treatment and multiple recurrences despite standard therapies …
by resistance to medical treatment and multiple recurrences despite standard therapies …
Synergism of checkpoint inhibitors and peptide receptor radionuclide therapy in the treatment of pituitary carcinoma
Context Aggressive pituitary tumors that have progressed following temozolomide have
limited treatment options. Peptide receptor radionuclide therapy and immunotherapy may …
limited treatment options. Peptide receptor radionuclide therapy and immunotherapy may …
相关搜索
- progress of immunotherapy pituitary carcinomas
- pituitary carcinoma inhibition therapy
- predictors of response pituitary tumors
- pituitary carcinoma efficacy of pembrolizumab
- pituitary carcinoma growth factor
- pituitary carcinoma checkpoint inhibitors
- pituitary carcinoma pembrolizumab in patients
- progress of immunotherapy pituitary adenomas